CD274 and non-small cell lung carcinoma: PD(L)1 checkpoint inhibitors now form part of the backbone of most therapeutic regimens in locally advanced and metastatic NSCLC, either as monotherapy or in combination with chemotherapy, offering significant improvements in the overall survival (OS) when compared with classic strategies.